Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical (NASDAQ: SWAV), a specialist in cardiovascular diseases, in a deal valued at approximately USD 13.1 billion. The acquisition, which is expected to close by mid-year 2024, will bring Shockwave’s innovative technologies into J&J’s medical technology unit, strengthening its position in the cardiovascular disease (CVD) market.
Shockwave Medical is renowned for its first-in-market intravascular lithotripsy (IVL) technology, a minimally invasive treatment for calcified coronary artery disease (CAD) and peripheral artery disease (PAD). This groundbreaking approach uses sonic pressure waves to break down calcium deposits, offering patients a less invasive alternative to traditional surgical methods. The company also has a novel product designed to alleviate symptoms of refractory angina.
The merger is set to establish J&J as a leader across four key CVD segments, including CAD and PAD, further expanding its reach in the medical technology space. This strategic move underscores J&J’s commitment to innovation in cardiovascular care and its ambition to transform the treatment landscape for patients suffering from these diseases.- Flcube.com
